Diridavumab

Diridavumab is a monoclonal anti-HA stalk antibody. Diridavumab stabilizes the prefusion HA structure and prevents pH-dependent fusion of cellular and viral membranes in endosomes. Diridavumab can be used in research of H2 influenza virus[1].

Product Specifications

CAS Number

[1393659-46-5]

Product Name Alternative

CR6261

UNSPSC

12352203

Target

Influenza Virus

Type

Inhibitory Antibodies

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/diridavumab.html

Purity

98.09

Solubility

10 mM in DMSO

Smiles

[Diridavumab]

Molecular Weight

(144.2 kDa)

References & Citations

[1]Sutton TC, et, al. In Vitro Neutralization Is Not Predictive of Prophylactic Efficacy of Broadly Neutralizing Monoclonal Antibodies CR6261 and CR9114 against Lethal H2 Influenza Virus Challenge in Mice. J Virol. 2017 Nov 30;91 (24) :e01603-17.